The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats

Figures & data

Table 1. Effects of JTT-751 and calcium carbonate on body weight, amounts of food consumption and parameters (Exp. 1).

	Control	1% JTT-751	1% Calcium carbonate	1% JTT-751 + 1% Calcium carbonate
Body weight (g, day 8)	392.1 ± 23.6	398.8 ± 44.6	389.5 ± 23.3	392.9 ± 20.6
Food consumption (g/day)	23.1 ± 2.0	23.3 ± 2.6	22.6 ± 0.9	22.7 ± 1.2
Creatinine
Urine (mg/day)	13.7 ± 1.3	14 ± 2	13 ± 0	13.3 ± 1.1
Serum (mg/dL, day 8)	0.26 ± 0.01	0.27 ± 0.05	0.24 ± 0.03	0.26 ± 0.02
Calcium
Urine (mg/day)	0.47 ± 0.11	0.57 ± 0.26	0.61 ± 0.06§	1.96 ± 0.30§
Serum (mg/dL, day 8)	9.48 ± 0.18	9.53 ± 0.18	9.45 ± 0.19	9.65 ± 0.19
Intact PTH
Serum (pg/mL, day 8)	157.570 ± 30.718	139.075 ± 55.663	100.042 ± 12.622§	74.273 ± 40.672§
Iron
Serum (μg/dL, day 8)	170 ± 19	173 ± 25	152 ± 19	164 ± 19
Hemoglobin
Blood (g/dL, day 8)	14.5 ± 0.7	14.5 ± 0.6	14.1 ± 0.5	14.6 ± 0.6
Reticulocyte
Blood (%, day 8)	2.0 ± 0.3	2.0 ± 0.3	1.9 ± 0.2	2.2 ± 0.4

n = 6. Data are mean ± SD. §p < 0.05 versus control group (Bartlett's test followed by Steel's test).

Figure 1. Effects of JTT-751, calcium carbonate and combined treatment on urinary, fecal and serum phosphorus in normal rats. (A) Mean urinary phosphorus excretion in 1% JTT-751 group, 1% calcium carbonate group and combined treatment group compared to control group. Data are the mean ± SD. §p < 0.05 versus control group (Bartlett's test followed by Steel's test). (B) Mean fecal phosphorus excretion. (C) Serum phosphorus level at day 8. §p < 0.05, §§p < 0.01 versus control group (Bartlett's test followed by Steel's test).

Table 2. Effects of JTT-751 and lanthanum carbonate on body weight, amounts of food consumption and parameters (Exp. 2).

	Control	0.3% Lanthanum carbonate	1% Lanthanum carbonate	3% Lanthanum carbonate	2.3% JTT-751
Body weight (g, day 8)	381.8 ± 15.9	393.4 ± 17.8	386.6 ± 25.0	387.4 ± 22.2	404.8 ± 26.6
Food consumption (g/day)	21.8 ± 1.1	22.8 ± 0.9	23.0 ± 1.7	22.3 ± 2.0	22.8 ± 1.8
Creatinine
Urine (mg/day)	13 ± 1	13.3 ± 0.7	13.3 ± 1.0	13 ± 1	13.5 ± 1.1
Serum (mg/dL, day 8)	0.27 ± 0.02	0.28 ± 0.02	0.27 ± 0.03	0.29 ± 0.02	0.28 ± 0.03
Calcium
Urine (mg/day)	0.55 ± 0.41	0.59 ± 0.46	0.37 ± 0.08	0.51 ± 0.40	1.18 ± 0.37†
Serum (mg/dL, day 8)	9.37 ± 0.21	9.43 ± 0.16	9.64 ± 0.17	9.53 ± 0.25	9.53 ± 0.19
Intact PTH
Serum (pg/mL, day 8)	156.979 ± 63.441	127.492 ± 39.736	132.472 ± 43.603	106.265 ± 28.176	113.471 ± 19.615

n = 5. Data are mean ± SD. †p < 0.05 versus control group (Bartlett's test followed by Dunnett's test).

Figure 2. Effects of JTT-751, lanthanum carbonate on urinary, fecal and serum phosphorus in normal rats. (A) Mean urinary phosphorus excretion in lanthanum groups and 2.3% JTT-751 group compared to control group. Data are the mean ± SD. §p < 0.05 versus control group (Bartlett's test followed by Steel's test). (B) Mean fecal phosphorus excretion. †p < 0.05 versus control group (Bartlett's test followed by Dunnett's test). (C) Serum phosphorus level at day 8.

Table 3. The phosphorus absorption-reducing efficacy of JTT-751, lanthanum carbonate and calcium carbonate.

	JTT-751	Lanthanum carbonate	Calcium carbonate
Phosphorus absorption-reducing efficacy (mg phosphorus/g anhydrous compound)	83 ± 22	19 ± 3	94 ± 18
Phosphorus absorption-reducing efficacy (mg phosphorus/mmol element)	19 ± 5 (Fe)	5 ± 1 (La)	10 ± 2 (Ca)

Data are mean ± SD.